KnollT. Epidemiology, pathogenesis and pathophysiology of urolithiasis. European Urology Supplements, 2010; 9(12):802–806.
2.
StamatelouKK, FrancisME, JonesCA, et al.Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int, 2003; 63(5):1817–1823.
3.
LjunghallS, LithellH, SkarforsE. Prevalence of renal stones in 60-year-old men. A 10-year follow-up study of a health survey. Br J Urol, 1987; 60(1):10–13.
4.
PearleMS, CalhounEA, CurhanGC. Urologic diseases in America project: Urolithiasis. J Urol, 2005; 173(3):848–857.
5.
NayanM, ElkoushyMA, AndonianS. Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. Can Urol Assoc J, 2012; 6(1):30–33.
6.
GentleDL, StollerML, BruceJE, et al.Geriatric urolithiasis. J Urol, 1997; 158(6):2221–2224.
7.
PakCY, PoindexterJR, Adams-HuetB, et al.Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med, 2003; 115(1):26–32.
8.
CurhanGC, WillettWC, SpeizerFE, et al.Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int, 2001; 59(6):2290–2298.
9.
SmithCL. Renal stone analysis: Is there any clinical value? Curr Opin Nephrol Hypertens, 1998; 7(6):703–709.
10.
FinkHA, WiltTJ, EidmanKE, et al.Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med, 2013; 158(7):535–543.
11.
EttingerB, CitronJT, LivermoreB, et al.Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol, 1988; 139(4):679–684.
12.
EttingerB, PakCY, CitronJT, et al.Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol, 1997; 158(6):2069–2073.
LaerumE, LarsenS. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand, 1984; 215(4):383–389.
15.
GoldfarbDS. Empiric therapy for kidney stones. Urolithiasis, 2019; 47(1):107–113.
16.
HsiRS, YanPL, GoldfarbDS, et al.Comparison of selective versus empiric pharmacologic preventative therapy with kidney stone recurrence. Urology, 2021; 149:81–88.
17.
GhiraldiEM, ReddyM, LiT, et al.Factors associated with compliance in submitting 24-hour urine collections in an underserved community. J Endourol, 2017; 31(S1):S64–S68.
18.
McGuireBB, BhanjiY, SharmaV, et al.Predicting patients with inadequate 24- or 48-hour urine collections at time of metabolic stone evaluation. J Endourol, 2015; 29(6):730–735.
DemirelA, SumaS. The efficacy of non-contrast helical computed tomography in the prediction of urinary stone composition in vivo. J Int Med Res, 2003; 31(1):1–5.
